Sino Biological US Inc

« Previous article
Sino Biological Offe...

19th January 2021  Product update: rapidmicrobiology staff writer

Panel of Recombinant Variants for COVID-19 Antigen Test Development & Validation 

Three fast-spreading new variants of SARS-CoV-2 virus have emerged in recent months: the U.K. variant B.1.1.7, the Brazil variant P.1, and the South Africa variant B.1.351.

A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain, although the three variants are believed to be independently evolved. These convergent mutations, specifically, the N501Y (shared by all three, 40592-V08H82) and E484K (shared between B.1.351 and P.1, 40592-V08H84), are of high interest because they may be the cause of the increased transmissibility.

The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. It’s critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.

Sino Biological has developed a panel of recombinant RBD/Spike and nucleocapsid protein variants carrying the aforementioned mutations. Click here for the full catalogue. 

Share on:


Date Published: 19th January 2021

Source article link: View

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.

View full company details

Sino Biological US Inc.


Wayne, PA 19087

United States

Tel: +1 215-583-7898

Email Supplier

View full company details

Related news from Sino Biological US Inc.